1. Home
  2. EVH vs CAPR Comparison

EVH vs CAPR Comparison

Compare EVH & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EVH

Evolent Health Inc

N/A

Current Price

$3.39

Market Cap

667.0M

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

N/A

Current Price

$8.94

Market Cap

584.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVH
CAPR
Founded
2011
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
667.0M
584.9M
IPO Year
2015
2011

Fundamental Metrics

Financial Performance
Metric
EVH
CAPR
Price
$3.39
$8.94
Analyst Decision
Buy
Buy
Analyst Count
14
10
Target Price
$5.75
★ $27.00
AVG Volume (30 Days)
1.5M
★ 2.4M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $907,957,000.00
N/A
Revenue This Year
$40.46
N/A
Revenue Next Year
$25.06
$1.52
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$2.10
$2.96
52 Week High
$8.46
$40.37

Technical Indicators

Market Signals
Indicator
EVH
CAPR
Relative Strength Index (RSI) 32.24 50.70
Support Level $2.53 $8.18
Resistance Level $3.68 $9.79
Average True Range (ATR) 0.18 0.52
MACD -0.02 0.15
Stochastic Oscillator 3.12 45.95

Price Performance

Historical Comparison
EVH
CAPR

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: